The AAPS Journal

, 21:10 | Cite as

Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information

  • Iris DetrezEmail author
  • Ganel Schops
  • Jolien Lefrère
  • Sophie Tops
  • Gert Van Assche
  • Séverine Vermeire
  • Wouter Van Moerkercke
  • Marc Ferrante
  • Ann Gils
Research Article


Development of a dried blood spot (DBS) method for golimumab will facilitate sample collection in a study setting and will give a more complete insight in the total drug exposure (area under the curve, AUC). We established a DBS method and assessed its robustness, user-friendliness and clinical usefulness in 10 patients with ulcerative colitis during golimumab induction and maintenance regimens. DBS was obtained through spotting of golimumab spiked in whole citrated blood to a filter paper. Several extraction conditions were evaluated and the selected extraction condition analytically validated. In a clinical setting, DBS and serum samples were taken simultaneously through intensive sampling regimens and a conversion factor was determined. Golimumab concentrations were measured using an in-house-developed ELISA and a CE-marked ELISA kit. User-friendliness was evaluated using a questionnaire. Mucosal healing was evaluated at week 14. A total of 79 matched pairs of serum and DBS sample golimumab concentrations revealed an overall conversion factor of 3.9. DBS golimumab concentrations after conversion correlated strongly with serum golimumab concentrations (ICC = 0.984). During induction, no linear correlation was found between golimumab trough concentration (TC) and AUC (R2 = 0.29). Multiple peaks emerged during drug absorption. Patients who achieved mucosal healing appeared to have less fluctuating TC and a constant AUC over time. Nine out of 10 patients reported DBS sampling as user-friendly. The GOUDA study showed that DBS sampling is a robust and patient-friendly alternative to venous blood collection. DBS sampling may provide better insights into golimumab absorption and exposure. ( NCT02910375)


dried blood spots golimumab immunogenicity pharmacokinetics ulcerative colitis 



This work was supported by the Fund for Scientific Research Flanders [TBM-T003716N], an investigator-initiated study grant received from Merck and the Flanders Innovation & Entrepreneurship to [ID].

Supplementary material

12248_2018_282_MOESM1_ESM.docx (13 kb)
ESM 1 (DOCX 13 kb)


  1. 1.
    Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER, Johns L, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs. 2010;2:428–39.CrossRefGoogle Scholar
  2. 2.
    Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85–95.CrossRefGoogle Scholar
  3. 3.
    Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:96–109.CrossRefGoogle Scholar
  4. 4.
    Bosca-Watts MM, Cortes X, Iborra M, Huguet JM, Sempere L, Garcia G, et al. Short-term effectiveness of golimumab for ulcerative colitis: observational multicenter study. World J Gastroenterol. 2016;22:10432–9.CrossRefGoogle Scholar
  5. 5.
    Tursi A, Allegretta L, Della Valle N, Hadad Y, Penna A, Pranzo G, et al. Effectiveness of golimumab in inducing remission and clinical response in outpatient ulcerative colitis. Clin Res Hepatol Gastroenterol. 2016;40:e61–3.CrossRefGoogle Scholar
  6. 6.
    Taxonera C, Rodríguez C, Bertoletti F, Menchén L, Arribas J, Sierra M, et al. Clinical outcomes of golimumab as first, second or third anti-TNF agent in patients with moderate-to-severe ulcerative colitis. Inflamm Bowel Dis. 2017;23:1394–402.CrossRefGoogle Scholar
  7. 7.
    Detrez I, Dreesen E, Van Stappen T, de Vries A, Brouwers E, Van Assche G, et al. Variability in golimumab exposure: a ‘real-life’ observational study in active ulcerative colitis. J Crohns Colitis. 2016;10:575–81.CrossRefGoogle Scholar
  8. 8.
    Adedokun O, Xu Z, Marano C, Strauss R, Zhang H, Johanns J, et al. Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2/3 PURSUIT induction and maintenance studies. J Crohns Colitis. 2017;11:35–46.CrossRefGoogle Scholar
  9. 9.
    Philip G, Marano C, Adedokun J, Melsheimer R, Cornillie FJJoCsaC. P698 Early dose optimisation in non-responders to golimumab induction treatment for ulcerative colitis is supported by pharmacokinetic data. 2018;12:S464–5.Google Scholar
  10. 10.
    Simponi, INN-golimumab. Summary of product characteristics. Available at: Accessed 28 Aug 2018.
  11. 11.
    Timmerman P, White S, Globig S, Lüdtke S, Brunet L, Smeraglia J. EBF recommendation on the validation of bioanalytical methods for dried blood spots. Bioanalysis. 2011;3:1567–75.CrossRefGoogle Scholar
  12. 12.
    Pugliese D, Felice C, Landi R, Papa A, Guidi L, Armuzzi A. Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis. Drug Healthc Patient Saf. 2016;8:1–7.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Bloem K, Schaap T, Boshuizen R, Kneepkens EL, Wolbink GJ, Ad V, et al. Capillary blood microsampling to determine serum biopharmaceutical concentration: Mitra® microsampler vs dried blood spot. Bioanalysis. 2018;10:815–23.CrossRefGoogle Scholar
  14. 14.
    Kneepkens EL, Pouw MF, Wolbink GJ, Schaap T, Nurmohamed MT, Vries A, et al. Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory diseases. Br J Clin Pharmacol. 2017;83:2474–84.CrossRefGoogle Scholar
  15. 15.
    Wilhelm AJ, den Burger JC, Swart EL. Therapeutic drug monitoring by dried blood spot: progress to date and future directions. Clin Pharmacokinet. 2014;53:961–73.CrossRefGoogle Scholar
  16. 16.
    Richter WF, Jacobsen B. Subcutaneous absorption of biotherapeutics: knowns and unknowns. Drug Metab Dispos. 2014;42:1881–9.CrossRefGoogle Scholar
  17. 17.
    Adedokun OJ, Xu Z, Marano CW, Strauss R, Zhang H, Johanns J, et al. Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2/3 PURSUIT induction and maintenance studies. J Crohns Colitis. 2016;11:35–46.CrossRefGoogle Scholar
  18. 18.
    Ducourau E, Ternant D, Lequerré T, Fuzibet P, Le Loët X, Watier H, et al. Towards an individualised target concentration of adalimumab in rheumatoid arthritis. Ann Rheum Dis. 2014;73:1428–9.CrossRefGoogle Scholar
  19. 19.
    Dreesen E, Gils A, Vermeire S. Pharmacokinetic modeling and simulation of biologicals in inflammatory bowel disease: the dawning of a new era for personalized treatment. Curr Drug Targets. 2018;19:757–76.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  • Iris Detrez
    • 1
    Email author
  • Ganel Schops
    • 2
  • Jolien Lefrère
    • 2
  • Sophie Tops
    • 1
  • Gert Van Assche
    • 2
  • Séverine Vermeire
    • 2
  • Wouter Van Moerkercke
    • 2
    • 3
  • Marc Ferrante
    • 2
  • Ann Gils
    • 1
  1. 1.Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic AntibodiesKU LeuvenLeuvenBelgium
  2. 2.Department of Gastroenterology and Hepatology, Translational Research in Gastrointestinal Disorders, UZ LeuvenKU LeuvenLeuvenBelgium
  3. 3.Department of GastroenterologyAZ GroeningeKortrijkBelgium

Personalised recommendations